Problem patents in innovator pharma

In this recent European Biopharmaceutical Review article, Lee and Vandana analyse freedom to operate from the innovator perspective in the pharmaceutical and biotechnology areas.

Here’s a link to the pdf – Think IP Strategy EBR Summer 2010

Please do let us know what you think.

5 Comments on “Problem patents in innovator pharma

  1. FTO analysis of particular product for IP clearance involves systematic search strategy. Apart from the patents available in the common data bases of USPTO,ESPACENET,PCT and other countries, search needs a comprehensive strategy to locate the problematic patent which otherwise would become an impediment for the IP clearance. K.M.Senthil Kumar

    Like

  2. Great, thanks so much Kmsenthil – so without giving away any secrets, what's your favourite search tool?

    Like

  3. My favourite search tool involves all the common data bases available in the public domain besides paid data bases such as Scifinder, STN, Delphion and so on. Despite being available as paid data bases, comprehensive search to locate the problematic patent is an art and involves complex and manipulated search strategy. K.M.Senthil Kumar

    Like

  4. In house IP clearance involving the said search strategy may bring a certain level of results. However, through FTO analysis may require out house IP clearance as well. K.M.Senthil Kumar

    Like

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: